Folic acid is enzymatically reduced and converted to tetrahydrofolate (THF) by dihydrofolate reductase via dihydrofolate. THF is converted to 5,10-methylenetetrahydrofolate (5,10-MTHF) by methylenetetrahydrofolate dehydrogenase and catalyzed to 5-methyltetrahydrofolate (5-MTHF) by methylenetetrahydrofolate reductase (MTHFR). 5-MTHF can be converted to THF again when a methyl group is passed to vitamin B12, resulting in methyl-vitamin B12. The methyl group from methyl-vitamin B12 can metabolize a cytotoxic molecule, homocysteine, into methionine. Homocysteine is also catabolized to cysteine by a vitamin B6-dependent enzyme, cystathionine β-synthase (CBS) [10] (Figure 1). Impaired metabolism of homocysteine is directly involved in increased incidence of NTDs; therefore, homocysteine levels are increased by the insufficiency of either vitamin B6, B12 or folic acid [11]. Daly et al. reported that folate levels were dose-dependently correlated with incidence risks of NTDs [12]. The threshold of red blood cell folate levels for minimizing the risk of NTDs of 906 nmol/L, equivalent to plasma folate levels of 7.0 ng/mL, has been established [12]. In particular, women with serum folate levels of